Overview

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of pertuzumab, trastuzumab and chemotherapy as a pertuzumab retreatment compared to trastuzumab and chemotherapy in locally advanced or metastatic breast cancer patients for previously treated with pertuzumab

Phase:

Phase 3

Details

Lead Sponsor:

Japan Breast Cancer Research Group

Collaborator:

Chugai Pharmaceutical

Treatments:

Albumin-Bound Paclitaxel
Capecitabine
Docetaxel
Gemcitabine
Paclitaxel
Pertuzumab
Trastuzumab
Vinorelbine